Tel: 01789 267520

Latest News: Research

Update on NHS England's position re EAP for SMA Type 1

10 May 2017 / Posted in: Research

You can now read the latest information about NHS England’s position on considering the possibility of supporting the costs of delivering the EAP in England. We now have authority to share information from the meeting we attended on 25th April with the NHS England Specialised Commissioning team.

Read full story

Cytokinetics Initiates Second Cohort in Phase 2 Trial of CK-2127107

26 April 2017 / Posted in: Research

Cytokinetics has announced that it has initiated enrolment of a second cohort of SMA patients with SMA Types 2, 3 or 4 in their phase 2 clinical trial of CK-2127107, in North America.

Read full story

Update on CHERISH and NURTURE clinical trials of Spinraza

25 April 2017 / Posted in: Research

Biogen and Ionis Pharmaceutical have released information on the CHERISH and NURTURE clinical trials of their gene therapy drug, Spinraza (formerly nusinersen).

Read full story

EMA recommends marketing authorisation for nusinersen

21 April 2017 / Posted in: Research

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the marketing approval of nusinersen.

Read full story

New Clinical Care Research Article: Scoliosis in SMA

18 April 2017 / Posted in: Research

This new research article looks at recent research into different aspects of spinal surgery, in the treatment of scoliosis in Spinal Muscular Atrophy.

Read full story

Biogen Announces EAP for Nusinersen Will Not Extend More Widely Than SMA Type 1

13 April 2017 / Posted in: Research

Biogen have set out their reasoning for this decision. We understand many families will be bitterly disappointed by this news.

Read full story

Clinicians' Open Letter about the EAP for Children with SMA Type 1 in the UK

06 April 2017 / Posted in: Research

Today, seventy clinicians, physiotherapists, study coordinators, industry and advocacy groups' representatives, including SMA Support UK, outline their position and recommendations to NICE, NHS England's Care and Clinical Reference Groups (CRGs), NHS Trusts and Biogen.

Read full story

AveXis announce results from AVXS-101 Phase I trial

05 April 2017 / Posted in: Research

AveXis has released results from the completed Phase I trial of their gene therapy drug for SMA, AVXS-101.

Read full story

Government Urged to Re-think its Proposed Changes to the HST Programme

29 March 2017 / Posted in: Research

SMA Support UK will today join Genetic Alliance UK and MDUK at the All Party Parliamentary Group for Muscular Dystrophy which NICE will also attend.

Read full story

The D4D Project

28 March 2017 / Posted in: Research

A workshop is taking place in London in January for people with a lived experience of genetic conditions as part of a new research project.

Read full story